Spinocerebellar ataxia type 3 (SCA3) is one of the most common dominantly inherited ataxias worldwide. Despite research advances, no approved disease-modifying treatment exists, and management focuses Show more
Spinocerebellar ataxia type 3 (SCA3) is one of the most common dominantly inherited ataxias worldwide. Despite research advances, no approved disease-modifying treatment exists, and management focuses on symptom alleviation and functional capacity maximization. Symptomatic treatment guidelines are scarce, leaving decisions to physicians' discretion. The lack of studies on SCA3 symptom management hinders therapy standardization. The aim of this study was to investigate medication-usage patterns among SCA3 mutation carriers and controls included in the multicentric European Spinocerebellar Ataxia Type-3/Machado-Joseph Disease Initiative (ESMI) cohort. We conducted a retrospective cross-sectional analysis of the medication taken by ESMI participants enrolled in the study between 2016 and 2023. Medication being used at the most recent follow-up visit available was categorized according to the Anatomical Therapeutic Chemical system. Comparisons between groups were performed using nonparametric tests for continuous variables and Fisher's exact test for categorical variables. In addition, a retrospective longitudinal analysis was conducted to study the impact of medication subclasses on disease progression, using linear mixed-effects models adjusted for relevant covariates. A total of 474 participants were included, comprising 344 SCA3 mutation carriers and 130 controls. Compared with controls, SCA3 subjects took more vitamins, mineral supplements, muscle relaxants, and medications targeting the nervous system. Psychoanaleptics and vitamins were introduced early in the disease course, whereas most other subclasses were initiated in mid-to-late stages, coinciding with the onset of neurological symptoms. Substantial disparities in medication usage were observed across the study centers. None of the medication subclasses commonly used by patients with SCA3 showed a significant impact on disease progression. This is the first study to explore medication usage patterns in SCA3 mutation carriers. Our study provides a comprehensive overview of the medications administered in SCA3 and underscores the importance of collaborative efforts toward achieving standardized clinical practices in the management of this disease. Show less
ArtInsight is an innovative dataset designed to detect deterioration in fine art, specifically easel paintings. The dataset includes high-resolution images captured at the University of Granada using Show more
ArtInsight is an innovative dataset designed to detect deterioration in fine art, specifically easel paintings. The dataset includes high-resolution images captured at the University of Granada using a digital camera with a 105 mm lens, ISO 125, F5, and a shutter speed of 1/13, and processed for color calibration. Two types of images are featured: those showing stucco technique interventions and those with Lacune from the loss of the Painting Layer (LPL). The VGG Image Annotator was employed for manual damage labeling, with annotations exported in JSON format and labeled for stucco and LPL damages. The dataset comprises 14 images with 2909 distinct damage areas, split into training and validation datasets. Developed using Python 3.7 and fine-tuned on a pre-trained Mask-RCNN model, this dataset demonstrates high accuracy rates (98-100 %) in damage detection. ArtInsight aims to facilitate automated damage detection and foster future research in art conservation and restoration. The dataset is publicly available at 10.5281/zenodo.8429814. Show less